Answers are grounded in this paper and cite their sources.
Biologics were introduced for the treatment of psoriasis in 2004 and during the past 5 years they have fundamentally changed the treatment of patients with moderate to severe psoriasis. In the November issue of the British Journal of Dermatology the British Association of Dermatology (BAD) guidelines on biologics were published, providing important up‐to‐date information on the management of patients with psoriasis using biologics.1 (Reprints of the guidelines are distributed with the print edition of this issue of the journal.) In this editorial, the question is addressed, ‘What is the actual relevance of biologics for the treatment of psoriasis?’ In particular, I will focus on long‐term safe treatment of psoriasis and changes in the treatment paradigm. Before the introduction of biologics, the treatment of psoriasis comprised on the one hand topicals, such as corticosteroids, vitamin D, tar and dithranol, and on the other hand systemics such as methotrexate, ciclosporin, acitretin and fumarates. In many patients, however, there remained an important unmet medical need with insufficient disease control and treatment‐induced comorbidities.2 In 2003, shortly before the introduction of biologics as routine treatment, a survey was conducted at three psoriasis outpatient clinics of university centres in Europe with a group of 301 patients who required more than topical treatment.2 Nearly 90% of these patients had received a least one systemic treatment or phototherapy for psoriasis and 39% had received three or more treatments. Inadequate response, no change or worsening, was observed in 10–50% of these patients and contraindications to conventional systemic treatments were reported by 9–22% of the patients. Overall 42% of the patients were not satisfied.
No takes yet. Share an insight, caveat, or question.
P.C.M. van de Kerkhof (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: